ET019003-T Cells in Relapsed/Refractory CD19+ B-Cell Leukemia and Lymphoma
Status:
Active, not recruiting
Trial end date:
2022-07-01
Target enrollment:
Participant gender:
Summary
This is a single center, open-label, 3+3 dose escalation, phase 1 study to evaluate the
efficacy and safety of ET019003-T cells therapy for patients with relapsed/refractory CD19+
acute lymphoblastic leukemia and lymphoma.